TNON leads healthcare surge +43.7% as EPS revisions power gains
Healthcare stocks dominated today's gainers after forward EPS estimates were revised sharply higher. Tenon Medical (TNON) jumped 43.7% to $7.07, Tempus AI (TEM) gained 27.9% to $66.65, and Intensity Therapeutics (INTS) rose 23.2% to $4.88. Harvard Bioscience (HBIO) climbed 22.4% to $7.55 after its Q2 beat and raised guidance, while Argenx (ARGX) advanced 21.9% to $1,038.12 on positive Phase 3 data.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| TNON | Healthcare | 2026-08-17 | +21.0pp | +43.7% |
| TEM | Healthcare | 2026-08-14 | +16.1pp | +27.9% |
| INTS | Healthcare | 2026-08-14 | N/A | +23.2% |
| HBIO | Healthcare | 2026-08-12 | +100.4pp | +22.4% |
| ARGX | Healthcare | 2026-08-14 | N/A | +21.9% |
Why did TNON stock jump in August 2026?
TNON jumped 43.7% (from $4.92 to $7.07) after its next-year EPS growth estimate was revised from 28.4% to 49.4% on August 17, a 21.0 percentage-point upward move.
The screener flagged the revision before any news hit the tape, and the stock has since rallied strongly as investors priced in the brighter outlook. With no earnings-related headlines in the window, the move appears driven entirely by the estimate upgrade, a sign the market is rewarding improving fundamentals.
TNON EPS revision history → · Screener snapshot from 2026-08-17 →
FAQ: TNON
Why did TNON stock jump?
Tenon Medical shares surged 43.7% to $7.07 after its next-year EPS growth estimate was revised upward from 28.4% to 49.4% on August 17, reflecting a 21.0 percentage-point improvement.
Is TNON a buy after the rally?
The stock has delivered a strong post-revision gain, but with no earnings news, the rally is driven by estimate momentum; investors should monitor whether the company can deliver on the higher EPS growth.
What is TNON's EPS growth estimate?
Tenon Medical's next-year EPS growth estimate was raised to 49.4%, up from 28.4%, representing a 21.0 percentage-point revision.
Why did TEM stock jump in August 2026?
TEM rose 27.9% (from $52.10 to $66.65) after its forward EPS growth estimate was revised from 97.3% to 113.5% on August 14, a 16.1 percentage-point jump.
The screener caught the revision early, and the stock has since rallied as investors bet on accelerated earnings expansion. With no earnings-related news in the window, the move underscores the market's sensitivity to upward estimate revisions in high-growth healthcare names.
TEM EPS revision history → · Screener snapshot from 2026-08-14 →
FAQ: TEM
Why did TEM stock jump?
Tempus AI shares gained 27.9% to $66.65 after its next-year EPS growth estimate was revised upward from 97.3% to 113.5% on August 14.
What is TEM's EPS growth estimate?
Tempus AI's next-year EPS growth estimate stands at 113.5%, up from 97.3%, a 16.1 percentage-point increase.
Is TEM a buy after the rally?
With a substantial upward EPS revision and no negative catalysts, TEM appears positioned for further gains, but the stock now trades at a premium following the 27.9% surge.
Why did INTS stock jump in August 2026?
INTS advanced 23.2% (from $3.96 to $4.88) after its current EPS growth for next year was reported at 30.4%, prompting a bullish repricing.
The screener identified the stock on August 14 before the move accelerated. Without earnings-related news, the gain appears tied to the positive EPS growth figure, lifting sentiment among small-cap healthcare investors.
INTS EPS revision history → · Screener snapshot from 2026-08-14 →
FAQ: INTS
Why did INTS stock jump?
Intensity Therapeutics shares climbed 23.2% to $4.88 after the screener flagged its next-year EPS growth estimate at 30.4%, signaling improved earnings potential.
What is INTS's EPS growth estimate?
Intensity Therapeutics' next-year EPS growth estimate is 30.4%, which was the key driver of the recent price surge.
Is INTS a buy after the rally?
The stock has gained 23.2% on the strength of its EPS estimate, but without accompanying news, investors should weigh the sustainability of this growth pace.
Why did HBIO stock jump in August 2026?
HBIO gained 22.4% (from $6.17 to $7.55) after its next-year EPS growth estimate was revised from 169.3% to 269.7% on August 12, a massive 100.4 percentage-point upgrade.
The catalyst came a day earlier when the company beat Q2 estimates, reporting an adjusted loss of $0.14 per share versus a $0.38 consensus, and raised its 2026 revenue guidance to 3-5% growth. The strong earnings call cited 11% revenue growth from CRO demand and double-digit expansion in telemetry and CMT portfolios, reinforcing the bullish EPS outlook.
HBIO EPS revision history → · Screener snapshot from 2026-08-12 →
FAQ: HBIO
Why did HBIO stock jump?
Harvard Bioscience shares rose 22.4% to $7.55 after its next-year EPS growth estimate was revised up from 169.3% to 269.7% following a Q2 earnings beat and raised guidance.
What caused HBIO's surge?
The surge was fueled by a Q2 beat (adjusted loss of $0.14 vs. $0.38 expected) and a raised 2026 revenue outlook, which drove a 100.4 percentage-point upgrade in EPS growth estimates.
Is HBIO a buy after the rally?
Given the strong earnings execution and the significant upward revision in EPS estimates, HBIO appears attractive, though the stock has already gained 22.4% since the revision.
Why did ARGX stock jump in August 2026?
ARGX jumped 21.9% (from $851.29 to $1,038.12) after its next-year EPS growth estimate was set at 31.6%, detected on August 14, with the rally accelerating on August 17 when positive Phase 3 ALKIVIA trial results were announced.
The trial of efgartigimod in autoimmune myositis met its primary endpoint (p=0.0011), with rapid and sustained treatment benefit, expanding the company's pipeline potential. The combination of a strong EPS growth estimate and a clinical catalyst drove the stock to record levels, reinforcing the bullish thesis.
ARGX EPS revision history → · Screener snapshot from 2026-08-14 →
FAQ: ARGX
Why did ARGX stock jump?
Argenx shares gained 21.9% to $1,038.12 after its next-year EPS growth estimate was set at 31.6% and positive Phase 3 results for efgartigimod in autoimmune myositis were announced on August 17.
What caused ARGX's surge?
The surge was driven by the Phase 3 ALKIVIA trial success, which met its primary endpoint, along with a solid EPS growth estimate of 31.6% for the next year.
Is ARGX a buy after the rally?
With a clinical win and a strong EPS growth outlook, ARGX appears well-positioned, but the rapid 21.9% gain warrants caution for new entries.
Today's movers highlight a strong healthcare rally driven by EPS estimate upgrades and clinical catalysts. The breadth of gains suggests investors are rotating into high-growth names with improving fundamentals, a signal of bullish sentiment in the sector.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →